Cargando…
Genetic Evidence Supporting Fibroblast Growth Factor 21 Signalling as a Pharmacological Target for Cardiometabolic Outcomes and Alzheimer’s Disease
Fibroblast growth factor 21 (FGF21) is a human metabolic hormone whose effects include modification of macronutrient preference and energy homeostasis. In animal models, FGF21 has been shown to have beneficial effects on cardiometabolic outcomes, Alzheimer’s disease risk and lifespan. In this study,...
Autores principales: | Larsson, Susanna C., Gill, Dipender |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146158/ https://www.ncbi.nlm.nih.gov/pubmed/33946944 http://dx.doi.org/10.3390/nu13051504 |
Ejemplares similares
-
Genetic predisposition to allergic diseases is inversely associated with risk of COVID‐19
por: Larsson, Susanna C., et al.
Publicado: (2021) -
Plasma Caffeine Levels and Risk of Alzheimer’s Disease and Parkinson’s Disease: Mendelian Randomization Study
por: Larsson, Susanna C., et al.
Publicado: (2022) -
Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia
por: Larsson, Susanna C., et al.
Publicado: (2021) -
Association of Serum Magnesium Levels With Risk of Intracranial Aneurysm: A Mendelian Randomization Study
por: Larsson, Susanna C., et al.
Publicado: (2021) -
Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
por: Karhunen, Ville, et al.
Publicado: (2021)